Feedback on opioid prescribing data improves clinicians' self-perceptions

Providing emergency department (ED) clinicians with feedback on their opioid prescribing led to a significant decrease in future prescriptions, according to a study published April 2 in Academic Emergency Medicine.

Led by Sean S. Michael, MD, assistant professor of emergency medicine at the University of Colorado Denver School of Medicine, researchers examined prescription practices among clinicians to identify if providing individualized feedback could change behavior. 

The study enrolled 51 physicians, residents and advanced practice providers, who were asked to self-identify and report their perceived opioid prescribing. These answers were then compared to their peers. 

Researchers found 65 percent underestimated their opioid prescribing. Additionally, clinicians who underestimated such rates prescribed fewer opioids than clinicians who did saw themselves within normal ranges.

“Self‐perception of prescribing was frequently inaccurate,” concluded Michael and colleagues. “Providing clinicians with their actual opioid prescribing data after querying their self‐perception reduced future prescribing among providers who underestimated their baseline prescribing. Our findings suggest that guideline and policy interventions should directly address the potential barrier of inaccurate provider self‐awareness.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.